Immunovant CLO exercises options and sells shares
Immunovant, Inc. Chief Legal Officer Christopher Van Tuyl reported same-day stock option exercises and open-market sales of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Immunovant, Inc. Chief Legal Officer Christopher Van Tuyl reported same-day stock option exercises and open-market sales of common stock. He exercised options for 17,824 shares at an exercise price of $15.20 per share and sold 17,824 shares in open-market transactions.
The reported sales were split into 2,842 shares at a weighted average price of $38.96 and 14,982 shares at a weighted average price of $38.19, with actual trade prices ranging from $37.75 to $39.15 per share. Following these transactions, he directly holds 180,597 Immunovant common shares and 53,707 stock options, which expire on April 1, 2035 and vest over time from an April 1, 2025 grant.
Insider Trade Summary
Exercise and Sale: 17,824 shares ($412K approx. pre-tax spread)
Exercise and Sale
4 txns
Insider
Van Tuyl Christopher
Role
Chief Legal Officer
Sold
17,824 shs ($683K)
Approx. gross sale proceeds
$683K
Approx. exercise cost
$271K
Approx. pre-tax spread
$412K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 17,824 | $0.00 | $0.00 |
| Exercise | Common Stock | 17,824 | $15.20 | $271K |
| Sale | Common Stock | 14,982 | $38.19 | $572K |
| Sale | Common Stock | 2,842 | $38.96 | $111K |
Holdings After Transaction:
Stock Option (right to buy) — 53,707 contracts (Direct);
Common Stock — 180,597 shares (Direct)
Footnotes (3)
- F1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.75 - $38.70 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.82 - $39.15 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- F3. Award of stock options to purchase Common Shares with a grant date of April 1, 2025. The shares underlying the option vest as to 25% on April 1, 2026, with the remainder vesting in 36 successive substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continued service to the Issuer as of such date.
Key Figures
Shares sold: 17,824 shares
Sale price block 1: $38.96/share
Sale price block 2: $38.19/share
+4 more
7 metrics
Shares sold
17,824 shares
Total Immunovant common shares sold in open-market transactions on June 26, 2026
Sale price block 1
$38.96/share
Weighted average price for 2,842 shares sold; trades ranged $37.75–$38.70
Sale price block 2
$38.19/share
Weighted average price for 14,982 shares sold; trades ranged $38.82–$39.15
Option exercise price
$15.20/share
Exercise price for 17,824 stock options converted into common stock
Shares held after
180,597 shares
Direct Immunovant common stock holdings after reported transactions
Options held after
53,707 options
Stock options to purchase Immunovant common stock after the exercise
Option expiration
April 1, 2035
Expiration date of the April 1, 2025 stock option grant
Key Terms
weighted average price, stock options, open-market sale, vesting, +1 more
5 terms
weighted average price financial
"The price reported is a weighted average price. These shares were sold in multiple transactions..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock options financial
"Award of stock options to purchase Common Shares with a grant date of April 1, 2025."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
vesting financial
"The shares underlying the option vest as to 25% on April 1, 2026, with the remainder vesting in 36 successive..."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Immunovant (IMVT) insider Christopher Van Tuyl report on this Form 4?
Christopher Van Tuyl reported exercising stock options for 17,824 Immunovant shares and selling 17,824 common shares in open-market transactions. The filing shows both the option exercise price and the weighted average sale prices for the trades.
What stock options did the Immunovant (IMVT) Chief Legal Officer exercise?
He exercised stock options covering 17,824 Immunovant common shares at an exercise price of $15.20 per share. These options are part of an April 1, 2025 grant that vests over several years, with the option award expiring on April 1, 2035.
What is the vesting schedule for the Immunovant (IMVT) options mentioned in the filing?
The options were granted on April 1, 2025 and vest 25% on April 1, 2026. The remaining 75% vest in 36 substantially equal monthly installments over the next three years, contingent on his continued service with Immunovant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
